A. O. Arduan

Nefropat?as hereditarias: nefropat?as glomerulares hereditarias

A. O. Arduan, 2007 .

Spanish multidisciplinary clinical practice guidelines for Anderson–Fabry disease in adults. I. Method and recommendations

M. D. Paz, E. P. D. L. Blanca, A. O. Arduan, 2019, Revista Clínica Española (English Edition).

Bisphenol A in Chronic Kidney Disease

J. Egido, E. González-Parra, A. O. Arduan, 2013, International journal of nephrology.

Efficacy of oral supplementation during dialysis in patients with chronic renal failure

P. Serván, A. O. Arduan, 2011 .

A combinatorial approach of Proteomics and Systems Biology in unravelling the mechanisms of acute kidney injury (AKI): involvement of NMDA receptor GRIN1 in murine AKI

Alberto Ortiz, Holger Husi, Harald Mischak, 2013, BMC Systems Biology.

Brain dysfunction in tubular and tubulointerstitial kidney diseases

G. Capasso, M. Zacchia, F. Trepiccione, 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Persistent acute renal failure in a patient infected with Plasmodium malariae: the importance of renal biopsy

A. O. Arduan, M. Picasso, S. Alexandru, 2020 .

Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes.

J. Donate-Correa, C. Mora-Fernández, A. O. Arduan, 2016, Cytokine & growth factor reviews.

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Eddie B. S. Tan, Nishit P. Parikh, Rajan K. Patel, 2023, The Lancet.

Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes.

J. Donate-Correa, C. Mora-Fernández, A. O. Arduan, 2016, Cytokine & growth factor reviews.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.